Advertisement

Topics

Idera Pharma Presents Pre-Clinical Data From IMO-2125 Treatment In Combination With Ipilimumab That Demonstrates Induction Of Durable Anti-Tumor Responses Associated With Tumor-Specific Memory

20:00 EDT 7 Sep 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Idera Pharma Presents Pre-Clinical Data From IMO-2125 Treatment In Combination With Ipilimumab That Demonstrates Induction Of Durable Anti-Tumor Responses Associated With Tumor-Specific Memory

NEXT ARTICLE

More From BioPortfolio on "Idera Pharma Presents Pre-Clinical Data From IMO-2125 Treatment In Combination With Ipilimumab That Demonstrates Induction Of Durable Anti-Tumor Responses Associated With Tumor-Specific Memory"

Quick Search
Advertisement